Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deucravacitinib - Bristol-Myers Squibb

Next Previous
Drug Profile

Deucravacitinib - Bristol-Myers Squibb

Alternative Names: BMS-986165; BMS-986165-01; Sotyktu

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Aniline compounds; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclopropanes; Ethers; Hepatoprotectants; Organic deuterium compounds; Pyridazines; Skin disorder therapies; Small molecules; Triazoles; Urologics
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Registered Erythrodermic psoriasis; Pustular psoriasis
  • Phase III Juvenile rheumatoid arthritis; Psoriasis; Psoriatic arthritis; Sjogren's syndrome; Systemic lupus erythematosus
  • Phase II Alopecia areata; Crohn's disease; Cutaneous lupus erythematosus; Discoid lupus erythematosus; Hidradenitis suppurativa; Lupus nephritis; Ulcerative colitis
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 11 Jun 2025 Deucravacitinib has a boxed warning for hypersensitivity and angioedema
  • 11 Jun 2025 Efficacy and adverse event data from the phase III POETYK PsA-1 trial in Psoriatic arthritis released by Bristol-Myers Squibb
  • 11 Jun 2025 Efficacy and adverse event data from the phase III POETYK PsA-2 trial in Psoriatic arthritis released by Bristol-Myers Squibb

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top